| Bladder Cancer |
1 |
1 |
| Biologic Therapy |
0 |
0.83 |
| Cancer |
0 |
0.73 |
| Chemotherapy |
0 |
0.52 |
| Combination Chemotherapy |
0 |
0.4 |
| Immunotherapy |
0 |
0.99 |
| Platinum |
0 |
0.3 |
| Genomic Medicine |
0 |
0.25 |
| Toxicology |
0 |
0.25 |
| Nucleoside Reverse Transcriptase Inhibitors |
0 |
0.21 |
| Hodgkin Lymphoma |
0 |
0.18 |
| Antibody Drug Conjugates |
0 |
0.17 |
| Food and Drug Administration (FDA) |
0 |
0.17 |
| Tyrosine Kinase Inhibitor |
0 |
0.17 |
| Bladder |
0 |
0.13 |
| Tumor |
0 |
0.09 |
| Brachial |
0 |
0.04 |
| Clinical Research |
0 |
0.04 |
| Fibroblast Growth Factor |
0 |
0.04 |
| Medical Oncology |
0 |
0.04 |
| Muscle |
0 |
0.04 |
| Receptors |
0 |
0.04 |
| Tyrosine Kinase |
0 |
0.04 |